Alzheimer Disease

Neurology·MeSH: Alzheimer Disease

Prevalence

700.0 / 100K

Incidence

120.0 / 100K/yr

46 drugs in development·26 companies·67 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
ZUNVEYL (formerly ALPHA-1062)	Alpha Cognition Inc. (ACOG)

Phase 3(7)

Drug	Company
[18f]pi-2620	Insight Molecular Diagnostics Inc. (IMDX)
Donanemab	ELI LILLY & Co (LLY)
Donepezil	Crinetics Pharmaceuticals, Inc. (CRNX)
KarX-EC	BRISTOL MYERS SQUIBB CO (BMY)
nio752	NOVARTIS AG (NVSEF)
simufilam	Filana Therapeutics Inc. (FLNA)
Simufilam	Filana Therapeutics Inc. (FLNA)

Phase 2(11)

Drug	Company
AL002	Alector, Inc. (ALEC)
ALN-APP	ALNYLAM PHARMACEUTICALS, INC. (ALNY)
ARO-MAPT	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
BMS-986446	PROTHENA CORP PUBLIC LTD CO (PRTA)
igc-ad1	IGC Pharma, Inc. (IGC)
igc-ad1-active	IGC Pharma, Inc. (IGC)
ly3202626	ELI LILLY & Co (LLY)
ly3372689	ELI LILLY & Co (LLY)
MK-1167	Merck & Co., Inc. (MRK)
primec	NeuroSense Therapeutics Ltd. (NRSN)
xpro1595	Inmune Bio, Inc. (INMB)

Phase 1(11)

Drug	Company
Dexmedetomidine	Applied Therapeutics, Inc. (APLT)
Dexmedetomidine and Midodrine	Applied Therapeutics, Inc. (APLT)
DNL628	Denali Therapeutics Inc. (DNLI)
flortaucipir f18	ELI LILLY & Co (LLY)
ion269	IONIS PHARMACEUTICALS INC (IONS)
lx1001	Lexeo Therapeutics, Inc. (LXEO)
ly3439539	ELI LILLY & Co (LLY)
ly3954068	ELI LILLY & Co (LLY)
ly4006895	ELI LILLY & Co (LLY)
nio752	Novartis AG (NVS)
pmn310	ProMIS Neurosciences Inc. (PMN)

Unknown(3)

Drug	Company
Florbetaben	ENANTA PHARMACEUTICALS INC (ENTA)
Flortaucipir	ENANTA PHARMACEUTICALS INC (ENTA)
Fluorodeoxyglucose	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1/Phase 2(2)

Drug	Company
ARO-MAPT-SC	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
snk01	NKGen Biotech, Inc. (NKGN)

Phase 2/Phase 3(1)

Drug	Company
ath-1017	LeonaBio, Inc. (LONA)

Phase 4(10)

Drug	Company
Dexmedetomidine	COGNITION THERAPEUTICS INC (CGTX)
Memantine	SUPERNUS PHARMACEUTICALS, INC. (SUPN)
Memantine Oral Tablet	SUPERNUS PHARMACEUTICALS, INC. (SUPN)
Simufilam 100 mg oral tablet	Filana Therapeutics Inc. (FLNA)
Xanomeline and Trospium Chloride Capsules	BRISTOL MYERS SQUIBB CO (BMY)
xanomeline enteric	BRISTOL MYERS SQUIBB CO (BMY)
Xanomeline Enteric Capsule	BRISTOL MYERS SQUIBB CO (BMY)
Xanomeline/Trospium Chloride Capsule	BRISTOL MYERS SQUIBB CO (BMY)
zunveyl	Alpha Cognition Inc. (ACOG)
zunveyl + memantine	Alpha Cognition Inc. (ACOG)

BioSniper tracks 46 drugs in development for Alzheimer Disease across 26 companies.

There are 67 clinical trials targeting Alzheimer Disease tracked by BioSniper.

The estimated prevalence of Alzheimer Disease is approximately 700.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.